A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-9966
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells ; volume:38 ; number:1 ; day:14 ; month:8 ; year:2019 ; pages:1-16 ; date:12.2019
Journal of experimental & clinical cancer research ; 38, Heft 1 (14.8.2019), 1-16, 12.2019

Urheber
Yu, Shengnan
Zhang, Jing
Yan, Yongxiang
Yao, Xudong
Fang, Lijuan
Xiong, Hui
Liu, Yang
Chu, Qian
Zhou, Pengfei
Wu, Kongming
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s13046-019-1354-1
URN
urn:nbn:de:101:1-2020010105023879720605
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:51 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Yu, Shengnan
  • Zhang, Jing
  • Yan, Yongxiang
  • Yao, Xudong
  • Fang, Lijuan
  • Xiong, Hui
  • Liu, Yang
  • Chu, Qian
  • Zhou, Pengfei
  • Wu, Kongming
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis

Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte

Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte

PYK2 promotes HER2-positive breast cancer invasion

PYK2 promotes HER2-positive breast cancer invasion

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

How We Treat HER2-Positive Metastatic Breast Cancer

How We Treat HER2-Positive Metastatic Breast Cancer

Nanotechnology approaches to addressing HER2-positive breast cancer

Nanotechnology approaches to addressing HER2-positive breast cancer

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer

Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer

Verbundene Objekte